What Is the RDI-Lancet Commission for Rare Disease and What Will It Achieve?
December 23, 2025 |
Christy Rohani-Montez, Medscape’s Rare Disease Education Lead recently spoke with Dr Lucy McKay, CEO, and Megan Pullein, Strategic Operations Officer from the UK-based charity Medics for Rare Disease (MfRD). We discussed their involvement in the recently formed RDI-Lancet Commission for Rare Diseases, a global initiative aimed at developing evidence-based recommendations to improve the lives of the 400 million people living with rare diseases worldwide.
Lucy McKay Megan Pullein
CEO Strategic Operations Officer
Medics for Rare Disease Medics for Rare Disease
Christy: It’s lovely to be speaking with one of our favourite partners in rare disease, Medics for Rare Disease! Lucy, and Megan, could you start by introducing yourselves, Medics for Rare Disease, and its mission?
Lucy: Absolutely, I’m Dr Lucy McKay, the CEO of Medics for Rare Disease, and our vision is simple: equitable healthcare for everyone. Our mission is to shape a medical profession that can provide timely diagnosis and excellent care to people living with rare diseases.
Megan: I’m Megan Pullein, and I’m the Strategic Operations Officer at Medics for Rare Disease. My primary role is to help manage our work with the RDI-Lancet Commission, specifically for Working Group 2, which Lucy Co-Chairs.
Christy: What are the Lancet Commissions, and what is the RDI-Lancet Commission for Rare Diseases?
Megan: The Lancet Commissions are in-depth research initiatives that tackle urgent and complex global health issues. They gather experts from around the world to collaborate on solutions, which are then published in the renowned medical journal. The vision for this specific commission is to make rare diseases visible globally, ensuring that every person is seen, heard, and cared for, no matter where they live. The goal is to produce actionable recommendations that any government can take and implement within their society.
Christy: I understand that the commission is divided into 5 working groups. What is the focus of each?
Lucy: Before breaking down the groups, it’s important to state the golden thread that runs through all of this: human rights. The entire commission is fundamentally about achieving equity for patients around the world.
Megan: That leads perfectly into Working Group 1, which is focused on visibility for human rights. This is the core of the commission. Working Group 2, which we are leading, focuses on visibility for social justice. These are the 2 overarching themes. The other groups are more specific: Group 3 is looking at data and metrics; Group 4 is tackling visibility within healthcare systems, particularly the diagnostic odyssey; and Group 5 is focused on clinical pathways and trials.
Christy: Where does the work for each group start, and where does it end?
Lucy: We’re working in 3 phases. For example, in Working Group 2, first is a comprehensive literature review to answer the question: is social justice being achieved for people living with rare disease? If so, how? And if not, why not?
The second phase is generating new evidence. We want to fill the gaps we find in the literature, especially from geographical and demographical sources that are currently missing. We have a lofty goal of trying to represent advocates from every UN-recognized country, starting with the places from which we hear no voices.
The final phase will be to consolidate this evidence into concrete recommendations.
Christy: What do you find most exciting about RDI-Lancet Commission?
Lucy: For The Lancet to even highlight Rare Disease is a major milestone in history. What excites me is that this project forces us to pull back to focus on the individual. We constantly have to ask, for example, How is this recommendation going to help someone in rural Chile? It moves the conversation beyond tech, molecules, and industry chatter. Tech doesn’t matter to people if they can’t access it or are being treated without the respect every human being deserves.
It allows us to establish a global standard of provision for the rare disease community and will help shape The World Health Organisation’s Global Action Plan for Rare Disease. We hope that in the future there will be greater standardisation and transparency in how nations care for rare diseases. This will empower the rare disease community to understand what they are entitled to, the barriers to access and to demand accountability.
Christy: Thank you so much Lucy and Megan, it’s exciting to see this research moving forward, and we’re all looking forward to seeing the forthcoming publications.
For more information on the RDI-Lancet Commission:
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00211-9/abstract
About Medscape Education
Medscape Education (medscape.org) is the leading destination for continuous professional development, consisting of more than 30 specialty-focused destinations offering thousands of free CME and CE courses for physicians, nurses, and other healthcare professional
This content was provided by Medscape Education
Company Details
Latest Content from Medscape Education
Abstract Highlights from EHA 2022 : A Spotlight on Lymphoma
Spotlight on LymphomaAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Dr Loretta Nastoupil, US, on the most important abstracts to look out for in...
TECHNOLOGY TRENDS AND THE FUTURE OF MEDICAL DEVICES
A MEDSCAPE DIGITAL HEALTH AND INNOVATION EVENT
Device Technology and Innovations
The world of medical device technology is constantly evolving. From wearable devices to diagnostic technology, clinicians have more options than ever for monitoring and assessing their patients' health. The accessibility...
The Power of AI in Medical Education
Artificial intelligence (AI) is a rapidly growing field with many applications in the world of medicine, including continuing medical education. Ritu Kumar, Medscape lead data scientist, explains how Medscape Education...
Connect to the conversation around mental health: A spotlight on physician burnout
For more than 2 years, the COVID-19 pandemic has put emphasis on an issue that has long affected healthcare workers and physicians -- burnout. Every year, Medscape surveys thousands of...
MEDSCAPE EDUCATION: The Human Story in Virtual Patient Simulation
WHAT'S THE STORYStories are shared experiences, where meaning-centered approaches and coping strategies ascribe cultural meaningto events and emotions; a way to merge the individual and the collective experience into the...
It’s a Medscape wrap for EHA2022
EHA2022 Hybrid Congress has now come to a close with the Thematic Days finishing last week. The Medscape team were delighted to connect with so many physicians, colleagues and supporters...
Part 4 of 4, of the Medscape video interview series
Dr. Hansa Bhargava MD interviews Dr. Maria Victoria Mateos on the most important abstracts to look out for in multiple myeloma and the potential implications of these data for managing patients...
Part 3 of the Medscape video series #EHA
Ahead of Europe’s largest hematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer, interviews Dr. Naval Daver on the most important abstracts to look out for in Myeloid and...
Part 2 of the Medscape video interview series
Ahead of Europe’s largest haematology conference Hansa Bhargava MD, Medscape Education Chief Medical Officer interviews Dr. John Gribben on the most important abstracts to look out for in CLL and the...